At Stuart Therapeutics, we are committed to developing differentiated and effective therapies for people living with chronic diseases of the eye. We are strong believers in the informed consent process, whereby patients gain a full understanding of the risks and benefits of participating in a clinical study for one of our drug candidates.
Please go to clinicaltrials.gov to learn more about participating in clinical trial studies, including the informed consent process, eligibility, risks and benefits of participation, and questions to ask.
Learn more about Stuart Therapeutics – sponsored clinical trials below.
A Phase 2 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Safety and Efficacy of ST-100 Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease
A Phase 3 Multi-Center, Randomized, Double Masked, Placebo Controlled Study to Assess the Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease
Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents for human therapeutic use in ophthalmology through license. At Stuart Therapeutics, we are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications. We are interested in strategic partner relationships that will extend and accelerate our impact.